Clinical Trial Update: A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating Boehringer Ingelheim's KISIMA-02 vaccine-based immunotherapy in combination with ezabenlimab for pancreatic ductal adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• KISIMA-02 vaccine-based immunotherapy (KISIMA-02 vaccine-based immunotherapy)
• ezabenlimab (ezabenlimab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Pancreatic Ductal Adenocarcinoma | Phase 1 | Status: ACTIVE_NOT_RECRUITING